Vanderbilt Center For Neuroscience Drug Discovery

Vanderbilt University’s Lee Limbird, Ph.D., has received one of pharmacology’s highest honors — the 2013 Julius Axelrod Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Read More

AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia. Read More

Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners. Read More

When discovering drugs for brain disorders, it’s important to test the candidates in multiple ways to avoid advancing those with restricted physiological effects. Read More

With the addition of a new 18,000-square-foot laboratory to be located within the Cool Springs Life Sciences Center, Vanderbilt University is expanding its research enterprise into Williamson County. Read More

Vanderbilt researcher and Gabon, Africa, native is working to discover ways to kill malaria-spreading mosquitoes. Read More

The progression of new drug candidates for schizophrenia with partner Janssen Pharmaceutica is the latest evidence that a new collaborative model for drug discovery pioneered at Vanderbilt may help identify and develop innovative candidate drugs for treatment of major brain disorders. Read More

Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects. Read More

The discovery of new compounds that work in a fundamentally different way than those in existing schizophrenia medications may allow for more normal function of brain cells involved in schizophrenia. Read More